MARKET

FGEN

FGEN

Fibrogen Inc
NASDAQ
10.04
+1.66
+19.81%
Pre Market: 9.75 -0.29 -2.89% 09:04 12/16 EST
OPEN
8.66
PREV CLOSE
8.38
HIGH
10.45
LOW
8.60
VOLUME
163
TURNOVER
--
52 WEEK HIGH
21.94
52 WEEK LOW
4.850
MARKET CAP
40.62M
P/E (TTM)
0.1882
1D
5D
1M
3M
1Y
5Y
1D
Is FibroGen (NASDAQ:FGEN) A Risky Investment?
Simply Wall St · 13h ago
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 1d ago
FibroGen: FDA Grants Orphan Drug Designation To Roxadustat For MDS
NASDAQ · 1d ago
FibroGen Wins FDA Orphan Drug Status for Blood Disorder Treatment Roxadustat
Benzinga · 1d ago
FibroGen granted orphan drug designation for roxadustat in MDS
TipRanks · 1d ago
FDA Grants Orphan Drug Designation to FibroGen's Roxadustat for Myelodysplastic Syndromes
Reuters · 1d ago
FIBROGEN INC - TO FILE PHASE 3 PROTOCOL IN Q4 2025
Reuters · 1d ago
ROXADUSTAT GRANTED ORPHAN DRUG DESIGNATION FOR THE TREATMENT OF MYELODYSPLASTIC SYNDROMES BY THE U.S. FOOD AND DRUG ADMINISTRATION
Reuters · 1d ago
More
About FGEN
FibroGen, Inc. is a biopharmaceutical company focused on the development of novel therapies at the frontiers of cancer biology and anemia. It is developing FG-3246, a potential first-in-class antibody-drug conjugate (ADC) targeting CD46, for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and potentially other cancers. This program also includes the development of FG-3180, an associated CD46-targeted positron emission tomography (PET) biomarker and imaging agent. It is also developing Roxadustat, an oral medication, first-in-class, oral small molecule hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI), which is evaluated for the treatment of anemia in patients with chronic kidney disease (CKD), anemia associated with myelodysplastic syndromes and chemotherapy-induced anemia. Roxadustat is approved in China, Europe, Japan, and numerous other countries for the treatment of anemia of CKD in adult patients on dialysis (DD) and not on dialysis (NDD).

Webull offers FibroGen Inc stock information, including NASDAQ: FGEN real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, FGEN stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading FGEN stock methods without spending real money on the virtual paper trading platform.